KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Operations (2018 - 2025)

Castle Biosciences' Cash from Operations history spans 7 years, with the latest figure at 26931000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 10.53% year-over-year to 26931000.0; the TTM value through Dec 2025 reached 64347000.0, down 0.8%, while the annual FY2025 figure was 64347000.0, 0.8% down from the prior year.
  • Cash from Operations for Q4 2025 was 26931000.0 at Castle Biosciences, up from 22631000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 26931000.0 in Q4 2025 and bottomed at 25439000.0 in Q1 2023.
  • The 5-year median for Cash from Operations is 3708500.0 (2021), against an average of 3147450.0.
  • The largest annual shift saw Cash from Operations plummeted 1346.61% in 2021 before it surged 733.86% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 2781000.0 in 2021, then tumbled by 115.75% to 6000000.0 in 2022, then skyrocketed by 409.78% to 18587000.0 in 2023, then surged by 31.09% to 24365000.0 in 2024, then increased by 10.53% to 26931000.0 in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Cash from Operations are 26931000.0 (Q4 2025), 22631000.0 (Q3 2025), and 20821000.0 (Q2 2025).